Predictive Oncology Inc.
POAI
$5.89
$0.346.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -7.69% | -95.99% | 2,151.02% | 91.36% | -99.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.69% | -95.99% | 2,151.02% | 91.36% | -99.42% |
| Cost of Revenue | -25.00% | 30.94% | 101.34% | 20.18% | -88.56% |
| Gross Profit | 35.62% | -129.03% | 470.45% | 312.60% | -101.26% |
| SG&A Expenses | 52.10% | 5.01% | -34.01% | -21.15% | -35.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.70% | 5.16% | -33.16% | -18.16% | -36.63% |
| Operating Income | -51.82% | -7.92% | 36.15% | 29.74% | 21.12% |
| Income Before Tax | -3,545.56% | 19.45% | 35.88% | 29.79% | 22.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3,545.56% | 19.45% | 35.88% | 29.79% | 22.50% |
| Earnings from Discontinued Operations | 99.47% | 87.36% | 75.94% | 85.78% | -132.43% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,409.19% | 34.92% | 42.09% | 37.57% | 2.17% |
| EBIT | -51.82% | -7.92% | 36.15% | 29.74% | 21.12% |
| EBITDA | -52.60% | -8.06% | 36.46% | 30.19% | 17.39% |
| EPS Basic | -1,377.88% | 66.67% | 67.11% | 62.01% | 38.34% |
| Normalized Basic EPS | -2,047.21% | 58.75% | 63.57% | 58.12% | 50.06% |
| EPS Diluted | -1,377.88% | 66.43% | 67.15% | 62.01% | 38.34% |
| Normalized Diluted EPS | -2,047.21% | 58.75% | 63.57% | 58.12% | 50.06% |
| Average Basic Shares Outstanding | 69.79% | 95.27% | 76.01% | 64.36% | 58.63% |
| Average Diluted Shares Outstanding | 69.79% | 95.27% | 76.01% | 64.36% | 58.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |